Compare LYFT Inc (LYFT) vs Merck & Co., Inc. (MRK) Price & Performance

LYFT IncTrade

Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

LYFT Inc vs Merck & Co., Inc. — how do they compare? LYFT Inc trades at $15.4 (market cap $5.86B), while Merck & Co., Inc. trades at $124.51 (market cap $307.25B). The key difference: Merck & Co., Inc. is far larger — about 52.4× LYFT Inc's market cap, and Merck & Co., Inc. pays a 2.73% dividend while LYFT Inc pays none. Which is the better fit depends on your goals.

	LYFT	MRK
Market Cap	$5.86B	$307.25B
Sector	Industrials	Health
52-Week High	$24.57	$129.52
52-Week Low	$12.65	$77.60
Enterprise Value	$5.39B	$350.66B
Dividend Yield	—	2.73%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

LYFT Inc

No Aura AI signal available yet.

Merck & Co., Inc.

Merck (MRK) trades at $126.02, down 1.16% on the day, with a neutral technical signal and bullish moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of -$1.28 beating expectations. Revenue grew to $65.01B in 2025, and net income margin improved to 28.07%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.

The outlook for MRK is positive, supported by robust fundamentals and analyst consensus, but risks include patent expirations and regulatory challenges. With a consensus price target of $137.30 offering ~9% upside, the stock presents a compelling opportunity for growth investors, though volatility from macroeconomic factors warrants caution.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

LYFT

View details →

MRK

Over 180 companies develop 200+ PD-1/PD-L1 inhibitors, reshaping cancer treatment landscape.Delveinsight · 3 hours agoBullish Schwab U.S. Dividend Equity ETF (SCHD) remains a Buy for strong dividends and growth potential.Seeking Alpha · 1 day agoBullish Merck rated Strong Buy on oncology growth and new LIPFENDRA launch for cholesterol controlSeeking Alpha · 4 days agoBullish View details →

About LYFT Inc

Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.